EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment

Tram T T Nguyen, Xuan T T Dang, Cao Dai Phung, Lan Thi Ngoc Tran, Nguyen Trong Phuoc Do, Eric Y M Yeo, Nhut Minh Tran, Brendon Zhi Jie Yeo, Celest P Lixuan, Nhung T H Nguyen, Hung Xuan Nguyen, Huong Thu Ngo und 3 weitere

Journal of Controlled Release · 2025

DOI: 10.1016/j.jconrel.2025.114239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Tram T T Nguyen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Extracellular Vesicles, Proto-Oncogene Proteins p21(ras), Oligonucleotides, Antisense. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A*STAR, National University of Singapore, Government of Singapore Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) often metastasizes to the peritoneum and is highly resistant to treatments due to its immunosuppressive microenvironment. In this study, we evaluate the safety and efficacy of a novel therapeutic strategy that combines KRAS-targeting antisense oligonucleotides (ASOs) with immunomodulatory RNA (immRNA), a RIG-I agonist, both delivered by extracellular vesicles (EVs), in preclinical models using PDAC patient-derived organoids and mice bearing PDAC peritoneal metastasis. Our data demonstrate that the combination of KRAS ASO and immRNA synergistically activates anti-tumor immune responses. EV-mediated co-delivery of both agents significantly inhibits tumor growth, reduces peritoneal metastasis, and markedly prolongs overall survival through the induction of immunologic cancer cell death. Importantly, this combination therapy is well-tolerated in non-human primates, with no observable changes in physical condition or behavior, blood parameters, or organ histology. These findings suggest that EV-delivered KRAS ASO and immRNA is a safe and potent therapeutic approach for treating PDAC and its peritoneal metastasis, positioning it as a promising strategy for future clinical advancement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsExtracellular VesiclesProto-Oncogene Proteins p21(ras)Oligonucleotides, AntisensePeritoneal NeoplasmsDEAD Box Protein 58Carcinoma, Pancreatic DuctalAnimalsHumansMiceCell Line, TumorFemaleMacaca fascicularisReceptors, Immunologic

Stichwörter der Autor:innen

Extracellular vesiclesKRAS mutationNon-human primate toxicityPancreatic ductal adenocarcinomaPeritoneal metastasisRIG-I agonist

Substanzen

Proto-Oncogene Proteins p21(ras)Oligonucleotides, AntisenseDEAD Box Protein 58KRAS protein, humanRIGI protein, humanReceptors, Immunologic

Autor:innen und Institutionen

  • Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Institute of Structural Biology, Nanyang Technological University, Singapore.
  • Vinmec-VinUni Institute of Immunology, Vin University, Viet Nam.
  • Vinmec-VinUni Institute of Immunology, Vin University, Viet Nam; Vinmec Hitech Center, Vinmec Healthcare System, Viet Nam.
  • Center for Research and Production of Vaccines and Biologicals, Viet Nam.
  • Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Institute for Health Innovation an…

Förderung

  • A*STAR
  • National University of Singapore
  • Government of Singapore Ministry of Health
  • National Medical Research Council

Zitieren

APA

Nguyen, T. T. T., Dang, X. T. T., Phung, C. D., Tran, L. T. N., Do, N. T. P., Yeo, E. Y. M., Tran, N. M., Yeo, B. Z. J., Lixuan, C. P., Nguyen, N. T. H., Nguyen, H. X., Ngo, H. T., Bonney, G. K., Luo, D., & Le, M. T. N. (2025). Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.114239

Vancouver

Nguyen TTT, Dang XTT, Phung CD, Tran LTN, Do NTP, Yeo EYM, et al. Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.114239

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Tram T T and Dang, Xuan T T and Phung, Cao Dai and Tran, Lan Thi Ngoc and Do, Nguyen Trong Phuoc and Yeo, Eric Y M and Tran, Nhut Minh and Yeo, Brendon Zhi Jie and Lixuan, Celest P and Nguyen, Nhung T H and Nguyen, Hung Xuan and Ngo, Huong Thu and Bonney, Glenn K and Luo, Dahai and Le, Minh T N},
  title = {Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment},
  journal = {Journal of Controlled Release},
  year = {2025},
  doi = {10.1016/j.jconrel.2025.114239}
}
Kostenlos starten →